Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Large-scale Brain Organization During Cognitive Control in ADHD: Complete Statistical AnalysisIndependent statistical analysis of Large-scale Brain Organization During Cognitive Control in ADHD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04349917).
- Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02125838).
- Laser Resurfacing Versus Dermabrasion for Scar Revision: Complete Statistical AnalysisIndependent statistical analysis of Laser Resurfacing Versus Dermabrasion for Scar Revision: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01176448).
- Laser Therapy for Treatment of Urogenital Symptoms in Women: Complete Statistical AnalysisIndependent statistical analysis of Laser Therapy for Treatment of Urogenital Symptoms in Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03681678).
- Laser Treatment for Vulvar Lichen Sclerosus: Complete Statistical AnalysisIndependent statistical analysis of Laser Treatment for Vulvar Lichen Sclerosus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04134494).
- LaserFissureIndependent statistical analysis of Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02357979).
- LASORIndependent statistical analysis of Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- LASSOIndependent statistical analysis of Allopurinol Outcome Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01391325).
- Late-Onset Treatment Study Extension Protocol: Complete Statistical AnalysisIndependent statistical analysis of Late-Onset Treatment Study Extension Protocol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00455195).
- Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: Complete Statistical AnalysisIndependent statistical analysis of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures: Complete Statistical AnalysisIndependent statistical analysis of Lateral Versus Anterior Spanning External Fixator for Tibial Plateau Fractures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00610701).
- LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: Complete Statistical AnalysisIndependent statistical analysis of LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Latino-SMARTIndependent statistical analysis of An Adaptive Intervention for Depression Among Latinos Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03668379).
- Laxative Effectiveness of a Phytotherapeutic Tea: Complete Statistical AnalysisIndependent statistical analysis of Laxative Effectiveness of a Phytotherapeutic Tea: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00872430).
- LBLIndependent statistical analysis of Harmonic Versus Electro Surgery in Lower Body Lift Procedures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00522171).
- LBPIndependent statistical analysis of Subacute Low Back Pain in Active Duty: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03502187).
- LCCC1407Independent statistical analysis of Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02276560).
- LCIOADMT2Independent statistical analysis of Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- LCSDecToolIndependent statistical analysis of Incorporating Veterans' Preferences Into Lung Cancer Screening Decisions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02899754).
- LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: Complete Statistical AnalysisIndependent statistical analysis of LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LDOTIndependent statistical analysis of Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00385684).
- LDP0114Independent statistical analysis of Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LEAD-2Independent statistical analysis of To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together:…
- LEADER 75Independent statistical analysis of Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- LEADER®Independent statistical analysis of Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- LEADER7Independent statistical analysis of Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- LEAPIndependent statistical analysis of AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05089708).
- LEAPIndependent statistical analysis of A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD): primary endpoint results, effect estimate with…
- LEAPIndependent statistical analysis of Lifestyle Enhancement for ADHD Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03690674).
- LEAPIndependent statistical analysis of Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- LEAP-001Independent statistical analysis of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAP-007Independent statistical analysis of Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] -…
- LEAP-OnIndependent statistical analysis of Persistence of Oral Tolerance to Peanut: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01366846).
- LEAP2Independent statistical analysis of Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- LEAPSIndependent statistical analysis of Locomotor Experience Applied Post Stroke Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00243919).
- Learn, Engage, Act, Process (LEAP) for MOVE!: Complete Statistical AnalysisIndependent statistical analysis of Learn, Engage, Act, Process (LEAP) for MOVE!: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02825680).
- Learning Direct Laryngoscopy Using a McGrath Video Laryngoscope as Direct Versus Indirect Laryngoscope: Complete Statistical AnalysisIndependent statistical analysis of Learning Direct Laryngoscopy Using a McGrath Video Laryngoscope as Direct Versus Indirect Laryngoscope: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Learning Impairments Among Survivors of Childhood Cancer: Complete Statistical AnalysisIndependent statistical analysis of Learning Impairments Among Survivors of Childhood Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00576472).
- Learning Skills Together Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Learning Skills Together Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04428034).
- LED Therapy for the Treatment of Concussive Brain Injury: Complete Statistical AnalysisIndependent statistical analysis of LED Therapy for the Treatment of Concussive Brain Injury: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02383472).
- Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval,…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: Complete Statistical AnalysisIndependent statistical analysis of Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: Complete Statistical AnalysisIndependent statistical analysis of LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02494921).